Next Article in Journal
Cancer-Associated Intermediate Conductance Ca2+-Activated K+ Channel KCa3.1
Next Article in Special Issue
Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma
Previous Article in Journal
FOSB–PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer
Previous Article in Special Issue
A DNA Vaccine Encoding SA-4-1BBL Fused to HPV-16 E7 Antigen Has Prophylactic and Therapeutic Efficacy in a Cervical Cancer Mouse Model
Review

Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells

by 1,†, 1,†, 2,3, 1,4, 5 and 1,5,*
1
Department of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
2
Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
3
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
4
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
5
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
*
Author to whom correspondence should be addressed.
Contributed equally.
Received: 30 November 2018 / Revised: 9 January 2019 / Accepted: 13 January 2019 / Published: 17 January 2019
(This article belongs to the Special Issue Cancer Vaccines: Research and Applications)
Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be a strategy to silence specific intracellular targets in DCs. This review provides an overview of the known negative immune regulators of DCs. Moreover, a combination of shRNA/siRNA and DC vaccines, DNA vaccines in animal models, and clinical trials are also discussed. View Full-Text
Keywords: dendritic cells (DCs); short-hairpin RNA (shRNA); small-interfering RNA (siRNA); intracellular negative immune regulator; cancer dendritic cells (DCs); short-hairpin RNA (shRNA); small-interfering RNA (siRNA); intracellular negative immune regulator; cancer
Show Figures

Figure 1

MDPI and ACS Style

Liu, Y.-H.; Yeh, I.-J.; Lai, M.-D.; Liu, K.-T.; Kuo, P.-L.; Yen, M.-C. Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells. Cancers 2019, 11, 108. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11010108

AMA Style

Liu Y-H, Yeh I-J, Lai M-D, Liu K-T, Kuo P-L, Yen M-C. Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells. Cancers. 2019; 11(1):108. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11010108

Chicago/Turabian Style

Liu, Yao-Hua, I-Jeng Yeh, Ming-Derg Lai, Kuan-Ting Liu, Po-Lin Kuo, and Meng-Chi Yen. 2019. "Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells" Cancers 11, no. 1: 108. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11010108

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop